KNSA Q4 2021 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena

KNSAKiniksa Pharmaceuticals, Ltd.

$3B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$19M

Gross Profit

$15M79.4% margin

Operating Income

-$36M-192.8% margin

Net Income

-$36M-193.8% margin

EPS (Diluted)

$-0.53

QoQ Revenue Growth

+55.0%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$19M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$233M

Total Liabilities

$48M

Stockholders' Equity

$185M

Cash & Equivalents

$122M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$19M	$0	—
Gross Profit	$15M	$0	—
Operating Income	-$36M	-$53M	+31.7%
Net Income	-$36M	-$54M	+32.3%